Financial Data and Key Metrics Changes - The net loss for Q2 2024 was $56 million or $0.97 per share, compared to a net loss of $37.2 million or $0.63 per share in Q1 2024 [4][26] - Total cash and investments on hand as of June 30, 2024, were $158.9 million, a decrease of $71.4 million from March 31, 2024 [6][27] - Costs and expenses from continuing operations for Q2 were $59.2 million, an increase of $20.1 million from Q1 2024 [28] Business Line Data and Key Metrics Changes - R&D expenses in Q2 included $17.6 million related to the manufacture of narsoplimab drug substance lots [5][26] - The company incurred $21.2 million in discounted term loan related debt repurchase and $1.9 million in transaction costs [5][27] - OMIDRIA royalties for Q2 were $10.9 million on net sales of $36.4 million, compared to $9.4 million on net sales of $31.2 million in Q1 2024 [29][30] Market Data and Key Metrics Changes - The company has two sales contingent milestones from the sale of OMIDRIA royalties, each up to $27.5 million, payable in January 2026 and January 2028 [6][30] - The debt repurchase transaction reduced the outstanding 2026 notes by 55% from $216 million to $98 million [7][32] Company Strategy and Development Direction - The company is focused on obtaining FDA approval for narsoplimab and is preparing for its resubmission [11][12] - The development program for zaltenibart (MASP-3 inhibitor) is advancing with multiple Phase 2 studies ongoing [13][16] - The company is exploring chronic large value indications for OMS1029, including neovascular age-related macular degeneration [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the data supporting narsoplimab's approval and is actively engaging with the FDA [38][41] - The company is well-prepared for commercialization upon receiving regulatory approval, with plans in place for packaging and branding [39][40] - Management highlighted the need for FDA approval as the primary requirement to move forward with narsoplimab [38][41] Other Important Information - The term loan agreement includes a $25 million delayed draw facility contingent on FDA approval of narsoplimab [9][31] - The company is developing a diagnostic approach for MASP-2 and lectin pathway hyperactivation to drive adoption of narsoplimab [22] Q&A Session Summary Question: Can you provide insights on future expenses? - Management clarified that the significant expenses incurred in Q2 are not expected to be repeated in the future [36] Question: What is needed for market entry post-approval? - Management indicated that FDA approval is crucial, and they are well-prepared for commercialization [38][40] Question: When is the additional FDA meeting expected? - The date of the meeting was not specified, but it involves responses to FDA questions [46] Question: What is the status of zaltenibart and C3G program? - The Phase 2 study is ongoing, and there is an expectation of overlap between Phase 2 and Phase 3 trials [53][54] Question: How quickly can OMS1029 enter the clinic? - If data is favorable, the company anticipates moving into the clinic in early 2025 [55]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34475 OMEROS CORPORATION (Exact name of registrant as specified in its charter) Washington 91-1663741 (State o ...

Exhibit 99.1 Omeros Corporation Reports Second Quarter 2024 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – August 7, 2024 – Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, as well as cancers and addictive and compulsive disorders, today announced r ...

Omeros Corporation (NASDAQ:OMER) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman and Chief Executive Officer Mike Jacobsen - Chief Accounting Officer Andreas Grauer - Chief Medical Officer Steve Whitaker - Vice President-Clinical Development Nadia Dac - Chief Commercial Officer Catherine Melfi - Chief Regulatory Officer Conference Call Participants Steve Brozak - WBB Securities Olivia Brayer - Cantor Fitzgerald Op ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the prece ...

Exhibit 99.1 Omeros Corporation Reports First Quarter 2024 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – May 15, 2024 – Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlig ...

Omeros Corporation (NASDAQ:OMER) Q4 2023 Earnings Conference Call April 1, 2024 4:30 PM ET Company Participants Peter Cancelmo - Investor Relations Gregory Demopulos - Chairman and Chief Executive Officer Michael Jacobsen - Chief Accounting Officer Steven Whitaker - Vice President, Clinical Development Catherine Melfi - Chief Regulatory Officer Nadia Dac - Chief Commercial Officer Andreas Grauer - Chief Medical Officer Conference Call Participants Olivia Brayer - Cantor Fitzgerald Stephen Brozak - WBB Secur ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to Commission file number: 001-34475 OMEROS CORPORATION (Exact name of registrant as specified in its charter) Washington 91-1663741 ...

Exhibit 99.1 Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – April 1, 2024 – Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced ...

Omeros Corporation (NASDAQ:OMER) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman & Chief Executive Officer Mike Jacobsen - Chief Accounting Officer Catherine Melfi - Chief Regulatory Officer Steve Whitaker - Vice President-Clinical Development Andreas Grauer - Chief Medical Officer Conference Call Participants Steve Brozak - WBB Securities Serge Belanger - Needham Operator Good afternoon, and welcome to today ...